Loading clinical trials...

Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes | Clinical Trials | Clareo Health

COMPLETED

Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes

A Single Center, Open Label, Longitudinal Single Arm Study to Compare the Efficacy and Safety of Prophylactic Famciclovir 500 mg b.d. in HIV Positive Adults With Recurrent Genital Herpes.

NCT01154543•Holdsworth House Medical Practice

View on ClinicalTrials.gov

Summary

To determine the efficacy of Famvir 500mg bd as suppressive antiviral therapy for acute genital Herpes simplex virus (HSV) outbreaks in HIV subjects.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Able to provide signed informed consent
•Documented HIV infection
•In general good health, without other serious medical conditions as deemed by the investigator
•Male or female over 18 years of age
•Diagnosed genital HSV (clinical or laboratory)
•Life expectancy of 12 months or longer per investigator's judgment
•Stable on Famvir 500 mg bd for at least 30 days at time of screening

Exclusion Criteria

•Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>5)mIU/mL).
•Women of childbearing potential who are unwilling to use reliable contraception for the duration of the study.
•History of hypersensitivity to Famvir, its constituents or penciclovir
•Current use of another antiherpetic medication
•Recent history of alcohol or drug abuse, which in the opinion of the investigator may interfere with their compliance with study requirements, or who have any other conditions which in the opinion of the investigator would interfere with the successful completion of study procedures
•Disorder or condition that could interfere with drug absorption, distribution, metabolism or excretion
•Known or suspected to have or past history of renal dysfunction requiring a dosage modification of Famvir 500 bd

Key Dates

Start Date

March 1, 2008

Primary Completion Date

January 1, 2013

Completion Date

February 1, 2013

Last Updated

March 20, 2013

Enrollment

ACTUAL participants

Conditions

HIV PositiveHerpes Simplex, Genital

Thinking and Memory Problems in People With HIV

NCT01875588

HIV Positive

View study

ENROLLING_BY_INVITATIONNA

Effect of Omega-3 Supplementation on Pregnant Outcomes and Inflammation Markers of Women Infected With HIV Using Antiretroviral Therapy

NCT06971445

Pregnant HIV Positive Women

View study

ACTIVE_NOT_RECRUITING

India HIV-CervCa Project

NCT07167069

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes

Inclusion Criteria

Exclusion Criteria

Thinking and Memory Problems in People With HIV

Effect of Omega-3 Supplementation on Pregnant Outcomes and Inflammation Markers of Women Infected With HIV Using Antiretroviral Therapy

India HIV-CervCa Project

Implementation and Effectiveness of a Psychosocial Intervention Among Registered People Living With HIV(HIV Patients) at Pakistan Institute of Medical Sciences (PIMS) Islamabad Pakistan.

CCTG 593: Testing and Linkage to Care

RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice